[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fekQHF_HLhLAI2VeUXbKzsmPRmq5R4V2iR0_-NF2CDGA":8,"$f0rEi2Bc2WFO2OIKU1UwMO2Wm8-tka041quWrQ4a3hu4":61,"$fCfT2NCGYzPkudorQ-PeTEd7M6eCnu4NFvCbCCej3rdE":62,"$fZ6DL-bCMn9uabDsL-LyISiqGskphx7DoqA43rG_jz58":66},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":60},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"roleType":17,"adept":18,"hospital":19,"department":20,"postsTitle":21,"materialTotal":17,"videoTotal":22,"isConcern":7,"title":23,"coverVertical":24,"coverAcross":25,"directionMarker":26,"description":27,"vid":28,"time":29,"mediaType":30,"views":31,"likes":17,"isThumbsUp":7,"isCollection":7,"collections":17,"createTime":32,"seoTitle":33,"seoKeywords":34,"seoDescription":35,"shelvesTime":36,"menus":37,"menuId":39,"type":26,"quality":57,"commentCount":17,"isComment":30,"deviceType":58,"url":59},7001,863398,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//W6OyePPo6ps051zACW5hlRIUH6DBCgnt.png","刘芬",0,"各种肿瘤的诊治","宁乡市人民医院","肿瘤科","主治医师",13,"免疫疗法+化疗：三期食管癌患者的生存转折点","https://cdn.yishi-tong.com/console/3/NYAm8Ud64IE_ndMKTqO1BOj3mEKOwvZ7.png","https://cdn.yishi-tong.com/console/3/ISbjhn-YjPzuYBD8PGwPewxzDNg3igQm.png",2,"\n\n大家好，我是宁乡市人民医院肿瘤科的刘芬医生。今天我们来聊一聊三期食管癌患者的治疗新选择，特别是免疫联合化疗的应用。\n\n以我们医院的一位患者陈建良为例，他是一位53岁的男性，近期被诊断为三期食管癌。尽管面临着这样的挑战，陈先生的生活习惯良好，入院时身体状况稳定，没有明显的不适。经过详细的检查，我们决定为他采用免疫治疗与化疗的联合方案。\n\n在治疗过程中，我们使用了替雷利珠单抗和卡培他滨这两种药物。替雷利珠单抗是一种免疫检查点抑制剂，能够增强患者自身免疫系统对肿瘤细胞的攻击。而卡培他滨则是一种口服化疗药物，能够有效抑制癌细胞的生长。两者的结合，旨在提高治疗效果，减少肿瘤的复发风险。\n\n免疫联合化疗的优势在于，它不仅可以直接杀死癌细胞，还能激活患者的免疫系统，使其在治疗后能够更好地识别和清除残留的癌细胞。这种方法在临床上显示出良好的疗效，尤其是在三期食管癌患者中，生存率有显著提高。\n\n当然，任何治疗方案都有其适用条件和潜在风险。免疫治疗可能会引发一些免疫相关的不良反应，如皮疹、腹泻等，但在陈先生的治疗过程中，他并没有出现显著的不良反应，身体状况保持稳定。这也说明了个体化治疗的重要性，医生会根据患者的具体情况来调整治疗方案。\n\n在出院时，我们为陈先生开具了卡培他滨片、利可君片和华蟾素胶囊，并强调了避免重体力劳动、加强营养和护理的重要性。同时，我们建议他定期复查血常规和肝肾功能，以便及时监测治疗效果和防止感染。\n\n总之，三期食管癌的治疗需要综合考虑多种因素，免疫联合化疗为患者提供了新的希望。希望通过这样的治疗，能够帮助更多患者战胜疾病，恢复健康。感谢大家的关注！","v0247cg10004d1553oqljhtddcec6tq0",183,1,514,"2025-06-03 14:07:06"," 免疫疗法+化疗：三期食管癌患者的生存转折点 | 最新治疗进展  \n"," 食管癌治疗, 免疫疗法, 化疗联合治疗, 三期食管癌, 生存率提升, 癌症免疫治疗, 肿瘤治疗方案  \n"," 探索免疫疗法联合化疗在三期食管癌治疗中的突破性进展，显著提高患者生存率。了解最新临床研究、治疗方案及患者受益情况，为食管癌患者提供新的希望。","2025-06-16 22:48:26",[38],{"menuId":39,"menuName":40,"parentId":17,"orderNum":41,"path":42,"component":43,"isFrame":44,"isCache":45,"menuType":46,"visible":30,"status":17,"createDept":6,"remark":47,"createTime":48,"children":49,"columnImage":50,"columnLogo":51,"uncheckedLogo":6,"checkedLogo":6,"isHot":17,"isHome":17,"forceLogin":17,"color":6,"seoTitle":52,"seoKeywords":53,"seoDescription":54,"contentNum":6,"promotionalPoster":55,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":56,"routerPath":42,"componentInfo":43},"1986622624134549505","科普视频",3,"video","/video.html","1","0","T","","2025-11-07 10:31:58",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:40/0d7fcb56-3dc4-4dcb-99ca-a5d5c438378e.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:43/958efac7-dd02-4681-b8fd-0dd84b1bbf42.png","健康科普视频大全,了解你的健康生活","健康科普视频, 戒烟视频, 饮食健康视频, 胸痛科普, 用药知识, 职业健康视频, 贫血科普, 眼健康视频","精选健康科普视频,涵盖戒烟、胸痛、饮食、用药与职业健康等多个主题,让你轻松获取科学健康知识,提升生活质量。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:09:45/fa8fe113-deaa-4454-8105-d629769963dd.png","Video","癌症肿瘤,重大疾病",4,"https://vod.haohuanjiao.com/huanjiao/specialistVideo/863398/c96c6423-6d93-47e1-801f-cd3ee13efa7b.tmp?a=0&auth_key=1789017940-b7eba0b49ea54a27b14ca83527083f05-0-8b997519fd13861717e35a83f24f300c&br=761&bt=761&cd=0%7C0%7C0&ch=0&cr=0&cs=0&dr=0&ds=3&eid=v0247cg10004d1553oqljhtddcec6tq0&er=0&l=202608110322324242E7520B9FF9326A2C&lr=&mime_type=video_mp4&net=0&pl=0&qs=13&rc=M3dmZmdrb3I4NDczNGY3M0ApdDloZ3dtdDY4ZzMzajo1eWduM2JhcWduMDJhLS1kNC9zcy1xYGBhZWlsMi4xLS5gMS06Yw%3D%3D&vl=&vr=",true,{"code":9,"msg":59,"message":6,"data":6,"success":60},{"code":9,"msg":10,"message":6,"data":63,"success":60},{"pageNo":30,"pageSize":64,"result":65,"totalSize":17},10,[],{"code":9,"msg":10,"message":6,"data":67,"success":60},{"authors":68,"appraiseDimensionScoresVos":69},[],[]]